COVID-19 trials registries data warehouse

https://anzctr.org.au/ACTRN12621001340820.aspx

Ngai Wah Cheung

wah.cheung@sydney.edu.au

2021-10-06

Not recruiting

RCT

Randomized

Parallel

Open label

multi-center

Treatment

1) have a confirmed diagnosis of COVID-19 2) are in a non-ICU ward, and are not imminently to be admitted to ICU or discharged 3) have known diabetes or newly diagnosed diabetes (diagnosed on an HbA1c >=6.5 mmol/L) 4) have had at least one fingerprick glucose level >=12 mmol/L since the commencement of dexamethasone.

1) pregnant 2) type 1 diabetes 3) eGFR <30

2

Prof NW Cheung

18

80

Australia

Moderate/severe disease at enrollment

4: Moderate/severe disease at enrollment

160

The primary outcome is the mean daily glucose level during the course of the trial. This will be calculated from glucose readings taken from before and after meals. Both formal venous and fingerprick glucose measurements will be accepted.[Daily pre and post meals; from the day of randomisation to the final day that the patient is in the trial.]

Phase 4

[{"arm_notes": "", "treatment_id": 1981, "treatment_name": "Isophane insulin", "treatment_type": "Hormones", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]